F2G, with Shionogi, said it has completed the data package needed to resubmit an NDA for orally administered olorofim. The company reported positive Phase III results showing noninferiority to IV-administered Ambisome (amphotericin B) for refractory aspergillosis or patients unsuitable for azoles, positioning olorofim for a renewed regulatory attempt.